Company intelligence / Profile preview

BioArts International

Mill Valley, California, United States

Ownership: Private
Development stage: Other

Overview

BioArts International was a biotechnology company primarily focused on the commercialization of pet cloning services. Founded by Lou Hawthorne, the company gained significant media attention for its "Best Friends Again" project, which offered dog cloning to the public. BioArts operated through a partnership with the Sooam Biotech Research Foundation in South Korea, utilizing somatic cell nuclear transfer (SCNT) technology. The company also held licenses for cloning technologies originally developed for the Dolly the sheep project. BioArts ceased its cloning operations in 2009, citing a small market, bioethical controversies, and increasing competition.

Modalities: Cell therapy
Industry: Veterinary

Partnerships

Sooam Biotech Research Foundation

Beyond the preview

Go deeper on BioArts International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioArts International.

Explore the full profile